UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

CRRL269: a novel designer and renal-enhancing pGC-A peptide activator

American journal of physiology. Regulatory, integrative and comparative physiology, 2018-03, Vol.314 (3), p.R407-R414

2018

Volltextzugriff (PDF)

CRRL269: A Novel Particulate Guanylyl Cyclase A Receptor Peptide Activator for Acute Kidney Injury

Circulation research, 2019-05, Vol.124 (10), p.1462-1472

2019

Volltextzugriff (PDF)

Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis

American journal of physiology. Regulatory, integrative and comparative physiology, 2013-01, Vol.304 (2), p.R102-R109

2013

Volltextzugriff (PDF)

Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation

American journal of physiology. Regulatory, integrative and comparative physiology, 2007-02, Vol.292 (2), p.R897-R901

2007

Volltextzugriff (PDF)

Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide

Hypertension (Dallas, Tex. 1979), 2019-04, Vol.73 (4), p.900-909

2019

Volltextzugriff (PDF)

Chronic Administration with Cenderitide Goes Beyond Enalapril in Cardiorenal Function and Anti-Remodeling Through Reverse Activation of Gene Pathways in Experimental Heart Failure

Journal of cardiac failure, 2016-08, Vol.22 (8), p.S15-S15

2016

Volltextzugriff (PDF)

CRRL269

Circulation research, 2019-05, Vol.124 (10), p.1462

2019

Volltextzugriff (PDF)

Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure

Circulation (New York, N.Y.), 2003-02, Vol.107 (5), p.686-689

2003

Volltextzugriff (PDF)

Gene Expression Profiling in Experimental Early Stage Heart Failure Reveals Activation of Molecular Pathways of Fibrosis and Inflammation in the Kidney and Heart

Journal of cardiac failure, 2014-08, Vol.20 (8), p.S74-S75

2014

Volltextzugriff (PDF)

Early activation of deleterious molecular pathways in the kidney in experimental heart failure with atrial remodeling

Physiological reports, 2017-05, Vol.5 (9), p.e13283-n/a

2017

Volltextzugriff (PDF)

Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure

Circulation. Heart failure, 2010-05, Vol.3 (3), p.412-419

2010

Volltextzugriff (PDF)

Pro-Atrial Natriuretic Peptide In Vitro and In Vivo Normal Canines: A Selective Renal Enhancing Therapeutic

Journal of cardiac failure, 2013-08, Vol.19 (8), p.S27-S27

2013

Volltextzugriff (PDF)

B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity

American journal of physiology. Regulatory, integrative and comparative physiology, 2009-06, Vol.296 (6), p.R1744-R1750

2009

Volltextzugriff (PDF)

Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure

Circulation (New York, N.Y.), 2005-08, Vol.112 (6), p.836-840

2005

Volltextzugriff (PDF)

Mineralocorticoid Escape by the Kidney But Not the Heart in Experimental Asymptomatic Left Ventricular Dysfunction

Hypertension (Dallas, Tex. 1979), 2007-09, Vol.50 (3), p.481-488

2007

Volltextzugriff (PDF)

Maximizing the natriuretic peptide system in experimental heart failure: Subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition

Circulation (New York, N.Y.), 2002-02, Vol.105 (8), p.999-1003

2002

Volltextzugriff (PDF)

Endogenous Natriuretic Peptides Participate in Renal and Humoral Actions of Acute Vasopeptidase Inhibition in Experimental Mild Heart Failure

Hypertension (Dallas, Tex. 1979), 2001-08, Vol.38 (2), p.187-191

2001

Volltextzugriff (PDF)

CRRL269 AS AN INNOVATIVE PARTICULATE GUANYLYL CYCLASE RECEPTOR (GC-A) PEPTIDE ACTIVATOR FOR ACUTE KIDNEY INJURY TREATMENT

Journal of the American College of Cardiology, 2019-03, Vol.73 (9), p.3065-3065

2019

Volltextzugriff (PDF)

Bioavailability of intravenous versus subcutaneous administration of the dual GC-A and GC-B designer natriuretic peptide cenderitide in healthy canines

BMC pharmacology, 2011-08, Vol.11 (S1), p.P11-P11, Article P11

2011

Volltextzugriff (PDF)

Neurohormonal Profile of a Novel Chimeric Natriuretic Peptide, CD-NP, as Compared to C-Type Natriuretic Peptide, in the Normal Dog

Journal of cardiac failure, 2007, Vol.13 (6), p.S144-S144

2007

Volltextzugriff (PDF)

Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide: NPA7

Hypertension (Dallas, Tex. 1979), 2019-04, Vol.73 (4), p.900-909

2019

Volltextzugriff (PDF)

Dipeptidyl Peptidase IV Inhibition with Sitagliptin Augments cGMP-Activating and Hypotensive Properties of B-Type Natriuretic Peptide

Journal of cardiac failure, 2008-08, Vol.14 (6), p.S75-S75

2008

Volltextzugriff (PDF)

Renal Mechanisms of Action of a Novel Designer Natriuretic Peptide, CU-NP

Journal of cardiac failure, 2008-08, Vol.14 (6), p.S79-S80

2008

Volltextzugriff (PDF)

Coadministration of the Vasopressin-2 Receptor Antagonist Tolvaptan and B-Type Natriuretic Peptide Enhances Water and Sodium Excretion without Adversely Affecting Renal or Neurohumoral Function in Experimental Congestive Heart Failure

Journal of cardiac failure, 2007, Vol.13 (6), p.S144-S144

2007

Volltextzugriff (PDF)

NPA7, A FIRST IN CLASS DUAL RECEPTOR ACTIVATOR WITH CARDIO-RENOPROTECTIVE PROPERTIES IN VIVO

Journal of the American College of Cardiology, 2017-03, Vol.69 (11), p.2554-2554

2017

Volltextzugriff (PDF)

1 – 25 von 89

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(83)
Mit Volltextzugriff
(84)

Publikationsform

Artikel
(89)

Sprache

Englisch
(89)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

CRRL269: a novel designer and renal-enhancing pGC-A peptide activator

CRRL269: A Novel Particulate Guanylyl Cyclase A Receptor Peptide Activator for Acute Kidney Injury

Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis

Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation

Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide

Chronic Administration with Cenderitide Goes Beyond Enalapril in Cardiorenal Function and Anti-Remodeling Through Reverse Activation of Gene Pathways in Experimental Heart Failure

CRRL269

Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure

Gene Expression Profiling in Experimental Early Stage Heart Failure Reveals Activation of Molecular Pathways of Fibrosis and Inflammation in the Kidney and Heart

Early activation of deleterious molecular pathways in the kidney in experimental heart failure with atrial remodeling

Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure

Pro-Atrial Natriuretic Peptide In Vitro and In Vivo Normal Canines: A Selective Renal Enhancing Therapeutic

B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity

Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure

Mineralocorticoid Escape by the Kidney But Not the Heart in Experimental Asymptomatic Left Ventricular Dysfunction

Maximizing the natriuretic peptide system in experimental heart failure: Subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition

Endogenous Natriuretic Peptides Participate in Renal and Humoral Actions of Acute Vasopeptidase Inhibition in Experimental Mild Heart Failure

CRRL269 AS AN INNOVATIVE PARTICULATE GUANYLYL CYCLASE RECEPTOR (GC-A) PEPTIDE ACTIVATOR FOR ACUTE KIDNEY INJURY TREATMENT

Bioavailability of intravenous versus subcutaneous administration of the dual GC-A and GC-B designer natriuretic peptide cenderitide in healthy canines

Neurohormonal Profile of a Novel Chimeric Natriuretic Peptide, CD-NP, as Compared to C-Type Natriuretic Peptide, in the Normal Dog

Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide: NPA7

Dipeptidyl Peptidase IV Inhibition with Sitagliptin Augments cGMP-Activating and Hypotensive Properties of B-Type Natriuretic Peptide

Renal Mechanisms of Action of a Novel Designer Natriuretic Peptide, CU-NP

Coadministration of the Vasopressin-2 Receptor Antagonist Tolvaptan and B-Type Natriuretic Peptide Enhances Water and Sodium Excretion without Adversely Affecting Renal or Neurohumoral Function in Experimental Congestive Heart Failure

NPA7, A FIRST IN CLASS DUAL RECEPTOR ACTIVATOR WITH CARDIO-RENOPROTECTIVE PROPERTIES IN VIVO

Suchergebnisse filtern